Table 3.
Prevalence of Oxalobacter formigenes Among 240 Control Subjects According to Antibiotic Use
| |
O. formigenes positive |
|
|
|
|---|---|---|---|---|
| Antibiotic last use | No. | (%) | Crude OR | MVOR (95% CI) |
| Sensitivea | ||||
| None | 51/92 | (55) | 1.0b | 1.0b |
| <1 year | 6/35 | (17) | 0.2 | 0.1 (0.05–0.4) |
| 1–5 year | 13/48 | (27) | 0.3 | 0.3 (0.1–0.6) |
| >5 year | 24/65 | (36) | 0.5 | 0.4 (0.2–0.8) |
| Nonsensitivec | ||||
| None | 67/161 | (42) | 1.0b | 1.0b |
| <1 year | 5/23 | (22) | 0.4 | 0.3 (0.1–1.0) |
| 1–5 year | 22/56 | (39) | 0.9 | 0.8 (0.4–1.6) |
a
Erythromycin, clarithromycin, azithromycin, tetracycline, minocycline, doxycycline, and metronidazole.
b
Reference category.
c
Ampicillin, amoxicillin, benzylpenicillin, dicloxacillin, penicillin NOS, cephalexin, cefadroxil, cefaclor, cefprozil, clindamycin, vancomycin, ciprofloxacin, levofloxacin, enrofloxacin, nitrofurantoin, trimethoprim, sulfamethoxazole, sulfa NOS, and antiobiotic NOS.